A Single Decoy Oligodeoxynucleotides Targeting Multiple Oncoproteins Produces Strong Anticancer Effects

@article{Gao2006ASD,
  title={A Single Decoy Oligodeoxynucleotides Targeting Multiple Oncoproteins Produces Strong Anticancer Effects},
  author={Huanhuan Gao and Jiening Xiao and Qiang Sun and Huixian Lin and Yunlong Bai and Long Yang and Bao-feng Yang and Hui-zhen Wang and Zhiguo Wang},
  journal={Molecular Pharmacology},
  year={2006},
  volume={70},
  pages={1621 - 1629}
}
Cancer in general is a multifactorial process. Targeting a single factor may not be optimal in therapy, because single agents are limited by incomplete efficacy and dose-limiting adverse effects. Combination pharmacotherapy or “drug cocktail” therapy has value against many diseases, including cancers. We report an innovative decoy oligodeoxynucleotide (dODN) technology that we term complex decoy oligodeoxynucleotide (cdODNs) in which multiple cis elements are engineered into single dODNs… 

Figures from this paper

Concomitant Targeting of Multiple Key Transcription Factors Effectively Disrupts Cancer Stem Cells Enriched in Side Population of Human Pancreatic Cancer Cells

TLDR
The findings indicate that targeting the key genes conferring the stemness of CSCs can efficiently eliminate CSC-like phenotypes, and thus may be considered a new approach for cancer therapy.

Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies

TLDR
Challenges remain in delivering effective doses of nucleic acid in vivo, but these are steadily being met, suggesting an optimistic future in the treatment of haematological malignancies.

Oxidized ultrashort nanotubes as carbon scaffolds for the construction of cell-penetrating NF-kappaB decoy molecules.

TLDR
The possibility to functionalize single-walled carbon nanotubes with decoy ODNs against nuclear factor-kappaB with covalent binding of amino-modified ODNs to carboxyl groups introduced onto SWCNTs through oxidation is evaluated.

Oligonucleotide delivery in cancer therapy

TLDR
This review summarizes the most meaningful non-viral strategies for ON delivery, including the chemical modifications of the ON backbone and non-Viral delivery systems.

Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer

TLDR
This paper aims to line out the description, design, and application of decoys in research and therapy of transcription factor targeted decoys, the new generation of functional gene downregulatory oligonucleotides which compete with specific binding sites of transcription factors.

The concept of multiple-target anti-miRNA antisense oligonucleotide technology.

TLDR
The multiple-target AMO technology or MT-AMO technology is an innovative strategy, which confers on a single AMO fragment the capability of targeting multiple miRNAs, and may find its broad application as a useful tool in miRNA research for exploring biological processes involving multiple mi RNAs and multiple genes.

A Novel Strategy for Mechanism Based Computational Drug Discovery

TLDR
A novel concept of ‘multiple-targeting’ that combines EGFR and Ras targeted therapy thereby providing a better therapeutic value against glioma is proposed.

INVESTIGATION OF THE MECHANISM AND THERAPEUTIC POTENTIAL OF A TRANSCRIPTION FACTOR DECOY TARGETING SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-3 (STAT3) FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

TLDR
Results indicate that targeting the EGFR-STAT3-Bcl-XL pathway at three distinct levels may be a promising treatment strategy for SCCHN.

References

SHOWING 1-10 OF 58 REFERENCES

E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells.

In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy

TLDR
Results suggest that a transcription factor decoy approach may be used to target STAT3 in cancers that demonstrate increased STAT3 activation including SCCHN.

Decoy Oligodeoxynucleotides As Novel Cardiovascular Drugs for Cardiovascular Disease

TLDR
This “decoy” strategy is not only a novel strategy for gene therapy as an antigene strategy, but also a powerful tool for the study of endogenous gene regulation in vivo as well as in vitro.

Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth

TLDR
Disruption of activated Stat3 by using a transcription factor decoy approach may serve as a novel therapeutic strategy for cancers characterized by constitutive Stat3 activation.

Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis

TLDR
In the authors' in vivo severe combined immunodeficient mouse model of human tumor growth and angiogenesis, combination treatment with low doses of LY294002, cisplatin and irradiation significantly inhibited the growth of human oral squamous carcinoma as well as prostate cancer.

Enhancement of ultraviolet-induced apoptosis by NF-kappaB decoy oligonucleotides.

TLDR
These data suggest that enhancement of UV-induced apoptosis by NF-kappaB decoy ODN may play a cancer-preventive role by further eliminating photodamaged keratinocytes.

A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.

TLDR
Transfection with E2F decoy inhibited expression of c-myc, cdc2, and the PCNA gene as well as vascular smooth muscle cell proliferation both in vitro and in the in vivo model of rat carotid injury.

Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.

Velcade, a proteasome inhibitor, has been shown to inhibit DNA binding activity of nuclear factor-kappaB (NF-kappaB) and to stabilize p53 in vitro. But its impact, in the context of activated

Therapeutic applications of transcription factor decoy oligonucleotides.

TLDR
The binding of these different factors, and the subsequent interactions of these proteins with each other, as well as with RNA polymerases or their cofactors, yield a complex set of conditions that determines the relative transcriptional activity at different times and under varying conditions in different cell types.
...